drugset / Trial / NCT06492954

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

NCT06492954

Phase 1 Recruiting 12 enrolled Emory University Genentech, Inc. · collab
NaSequentialOpen-labelTreatment

Summary

This study aims to determine the safety and tolerability of combined Atezolizumab, stereotactic body radiation therapy (SBRT), and surgical resection of pulmonary metastases in patients with pulmonary recurrence of osteosarcoma

Timeline

Start
2026-07
Primary completion
2027-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Atezolizumab Monoclonal antibody 15 mg/kg Intravenous
Subject Atezolizumab Monoclonal antibody 1200 mg Intravenous